{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000048","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-06-30T20:06:32+00:00","discovered_at":"2026-06-30T20:07:01.387686+00:00","generated_at":"2026-06-30T20:07:07.860215+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Xeris appoints Nerissa Kreher to board; CEO John Shannon named Chair","bullets":["Dr. Nerissa Kreher appointed to board effective July 1, 2026, expanding board to eight members.","CEO John Shannon named Chair of the Board effective July 1, 2026.","Marla Persky transitions to Lead Independent Director.","Dr. Kreher is CMO of Alltrna and has over 20 years of rare disease experience.","Dr. Kreher received initial equity award of ~$450,000 in options and RSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000048","json":"https://secwatch.observer/filing/0001867096-26-000048.json","markdown":"https://secwatch.observer/filing/0001867096-26-000048.md","text":"https://secwatch.observer/filing/0001867096-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/0001867096-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/xers-20260629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:07:07.860215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}